Our core strength lies in our research and development capabilities in the field of topical formulations and transdermal delivery.

Applying skin science to deliver novel topical treatments

Futura’s unique technology, expertise and know how, enables targeted and rapid delivery of active pharmaceutical ingredients (API) and Generally Recognized As Safe (GRAS) pharmaceutical excipients onto and through the skin to the required site of action with a high level of safety.

Our versatile transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products or creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules and with potentially a shorter regulatory pathway.

At the core of Dermasys®

Combination of volatile solvent components creates an evaporative action

With active drug

With excipients

Targeted and rapid delivery through the skin

The combination of volatile solvent components, gentle penetration enhancers and active creates a concentration gradient that drives the active through the skin.

Local targeted physical action

The combination of volatile solvent components creates an evaporative and novel action that stimulates nerve sensors and creates a physical action.

DermaSys® and the process behind our unique formulations

Our unique patented technology DermaSys® is designed to deliver clinically proven effective medical treatments via the skin.

DermaSys® is a versatile and bespoke technology. Each gel is uniquely formulated using the DermaSys® platform with volatile solvent and/or penetration enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile reducing the risk of side effects. Each product is formulated to maximise its benefits for patients and consumers. Each new unique formulation offers the opportunity for additional patent applications and potential patent protection.

The gels we develop are versatile, clear and odourless and provide effective and local topical application to the required site of action. For our erectile dysfunction treatment, MED3000, this translates into a fast-acting treatment for erectile dysfunction with an excellent safety profile. For our pain relief treatments, TPR100 and TIB200, this translates into effective penetration for enhanced therapeutic benefits with fast, effective and long-lasting relief.

Proprietary Dermasys® Technology

Combined with Futura's know-how and expertise in formulation

Target product profile to deliver unique benefits to patients and consumers

Gel Specifically tailored and formulated

MED3000

  • Fast onset of action
  • Duration of action to suit the natural length of intercourse
  • Excellent safety profile

TPR100

  • Fast delivery of the active diclofenac through the skin
  • Superior absorption
  • 12 hour efficacy for twice daily dosing

Strong IP

DermaSys® is a proprietary transdermal technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments.

Each new unique formulation offers the opportunity for additional patent applications and potential patent protection. We protect this valuable IP and ensure that we maximise both the strength of our patents’ protection and their duration.  Aside from our current patent lawyers, Futura recently retained a specialist biotech IP and strategic advice company to assist in maximising the robustness of the MED3000 intellectual property.